Abgenix Inc.

Abgenix, a biopharmaceutical company, develops and intends to commercialize antibody therapeutic products for the treatment of a variety of disease conditions, including transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious disease and cancer. Abgenix develops human antibody products from its Xenomouse transgenic mouse technology for treating GVHD, psoriasis, arthritis, and cancer. Abgenix has developed a proprietary technology which enables the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy (XenoMouse™ Technology). Abgenix intends to use its XenoMouse technology to build and commercialize a large and diversified product portfolio through the establishment of corporate collaborations and internal product development programs. Abgenix has collaborative arrangements with multiple pharmaceutical, biotechnology and genomics companies involving this technology. In addition, Abgenix has three proprietary antibody product candidates in human clinical trials.

Activity:

- Manufacturing
- Research & Development

Product / Technology type(s) covered:

- Bio
- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: